We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

By LabMedica International staff writers
Posted on 07 Jun 2016
Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. More...


The three-dimensional print electronics developer Nano Dimension (Ness Ziona, Israel) collaborated with Accellta (Haifa, Israel), which has developed proprietary technologies for the production of high quality media, stem cells, progenitors, and differentiated cells for drug discovery, regenerative medicine, and research.

The partners recently announced that they had successfully tested a proof-of-concept three-dimensional bioprinter for stem cells. The ability of the printer to generate stem cells was due in part to Accellta's robust and reproducible suspension-based cell culturing systems that produce billions of high quality stem cells per batch.

Amit Dror, CEO of Nano Dimension, said, "Three-dimensional printing of living cells is a technology that is already playing a significant role in medical research, but in order to reach its full potential, for the field to evolve further, there is a need to improve printing speeds, print resolution, cell control, and viability as well as cell availability and bio-ink technologies. By combining our high speed, high precision inkjet capabilities with Accellta's stem cell suspension technologies and induced differentiation capabilities led by a world-renown group of experienced engineers and scientists, we can enable three-dimensional printing at high resolution and high volumes."

Dr. Itzchak Angel, CEO of Accellta, said, "Accellta and Nano Dimension have joined forces in this initial trial to evaluate and adapt the joint potential of our technologies. We hope and believe that this will bring the mutual capabilities and know-how of both companies to create three-dimensional bioprinting solutions that combine a high precision, high-throughput printer with dedicated bio-ink technologies, derived from stem cells. By enabling high precision three-dimensional bioprinting and differentiation of stem cells into required tissues, our combined technologies have the potential to enable vast areas of development."

Related Links:
Nano Dimension
Accellta

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Repetitive Pipette
VWR® Stepper Pro
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.